NG00066 - ADNI-WGS-1


The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a longitudinal multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer’s disease (AD). ADNI began in 2004, funded as a private-public partnership. The initial five-year study (ADNI-1) was extended by two years in 2009 by a Grand Opportunities grant  (ADNI-GO), and in 2011 and 2016 by further competitive renewals of the ADNI-1 grant (ADNI-2, and ADNI-3, respectively). New participants were recruited across North America during each phase of the study and agreed to complete a variety of imaging and clinical assessments. Participants are followed and reassessed over time to track the pathology of the disease as it progresses.

Whole Genome Sequencing Data
In July 2012, the Brin-Wojcicki Foundation and the Alzheimer’s Association donated funds to support whole genome sequencing (WGS) of 818 ADNI participants (at the time: 128 with AD, 415 with MCI, 267 controls and 8 of uncertain diagnosis). Samples were sent to Illumina, where non-CLIA WGS, as well as Illumina Omni 2.5M genome-wide association study (GWAS) single nucleotide polymorphism (SNP) arrays, were performed on each sample and completed in Spring 2013. Basic quality control checks were then performed and additional checks are continually performed. For more information:

Data Access
GWAS data can be obtained directly from ADNI while sequencing data mapped to GRCh38 and harmonized with ADSP data are available through qualified access from NIAGADS DSS. Approval from both the DSS and LONI are required in order to access the sequencing data. 


Molecular Data Type




PI Information

Administrative Core PI                                           Genetics Core PI
Michael W. Weiner, M.D.                                        Andrew J. Saykin, Psy.D.
UCSF, NCIRE, VA Medical Center                          Indiana University